newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics Provides a Corporate Update and Business Outlook

Outlook Therapeutics advancing first ever ophthalmic formulation of bevacizumab towards new U.S. FDA Biologics License Application (BLA) submission, anticipated this quarter ONS-5010 / LYTENAVA™ (bevacizumab-vikg) expected to receive, if approved, 12